Drug Trial Radar · NCT07858344
Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIb Clinical Trial of Spray YJ001 for the Treatment of Diabetic Peripheral Neuropathic Pain
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Jan 18, 2024
Primary completion
Dec 27, 2024
Study completion Jan 3, 2025
Sponsor
- Lead sponsor
- Zhejiang Yuejia Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if YJ001 Spray can treat diabetic patients with Diabetic Peripheral Neuropathic Pain(DPNP). The main questions it aims to answer are: * Is YJ001 spray effective for patients with diabetic peripheral neuropathic pain(DPNP)? * The optimal effective dose of YJ001 spray for patients with diabetic peripheral neuropathic pain(DPNP). * Is YJ001 spray safe for patients with diabetic peripheral neuropathic pain(DPNP)? Researchers will divide YJ001 spray into three different doses of YJ001 spray and compare it with a placebo (a substance that looks similar but does not contain medication) to observe whether YJ001 spray can effectively treat diabetic peripheral neuropathic pain and to determine the optimal effective dose. Participants will: * Apply spray topically to both feet twice daily, with six sprays per foot at each administration.Attend scheduled study visits at baseline and weeks 1, 2, 4, 8, and 12, followed by a visit 1 week after Treatment termination. * Record their symptoms and the number of times they use the spray.
Conditions
- Diabetic Peripheral Neuropathic Pain (DPNP)
Interventions
YJ001 spray simulatorDrug
YJ001 spray 0mg/ml,apply spray to both feet 0mg each time,twice daily, with six sprays per foot.
YJ001 Spray 240 mg/dayDrug
YJ001 spray 50mg/ml,apply spray to both feet 120mg each time,twice daily, with six sprays per foot.
YJ001 Spray 480 mg/dayDrug
YJ001 spray 100mg/ml,apply spray to both feet 240mg each time,twice daily, with six sprays per foot.
YJ001 Spray 960 mg/dayDrug
YJ001 spray 200mg/ml,apply spray to both feet 480mg each time,twice daily, with six sprays per foot
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in weekly average Numeric Rating Scale (NRS) pain score at Week 12 after treatment.Time frame: baseline and week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Haidian District, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.